Clinical trial · Observational
Comprehensive Therapy to Relieving the Risk of Recurrence and Metastasis for Colorectal Cancer
Retrospective-Prospective Cohort Study Effectiveness of Comprehensive Therapy of TCM to Relieving the Risk of Recurrence and Metastasis for Stage II & III Colorectal Cancer Based on Conventional Western Medicine Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Comprehensive therapy of traditional Chinese medicine (CTTCM) could relieve risk of recurrence and metastasis for stage II \& III colorectal cancer, the investigators take this clinical trial with retrospective-prospective cohort study based on previous studies by international multi-center way. If the study shows a positive result, a pragmatic randomized controlled study with prospective, multi-centre and large-sample design will be given continuously. The aim is to establish recommended programs suggested by CTTCM strategies under conventional Western medicine therapy (CWMT) for stage II \& III colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- CTTCT+CWMT
- description
- CTTCM:taking TCM decoction based on syndrome differentiation daily and each dosage is decocted two times for intervention one year with a Chinese patent medicine at least. CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline).
- label
- CWMT cohort
- description
- CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline).
Primary outcomes (1)
- measure
- The recurrence and metastasis rates for 1、2、3、4 and 5-year.
- timeFrame
- one year
Secondary outcomes (1)
- measure
- Survival index: the survival rate for1、2、3、4 and 5-year.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patient who is diagnosed colorectal cancer by patho\& cytologic diagnosis since accepting radical operation within half a year. * Stage II or III colorectal cancer. * 18-75 yr. * Being able to participate and sign the informed consent. Exclusion Criteria: * Pregnant woman, Psychotic. * Patient who put together with other cancer. * Existed serious complaint and functional disturbance (impairment) with non-tumorous in arch-organ. * Reactiveness cerebrovascular disease (CVD) . * Uncontrolled infection and metabolic disease. * One item of tumor marks is progressed, and it still is progressed when patient recheck. * Tumor that it is neo-occurred in each organ or pelvic cavity or abdominal cavity without definite patho-quality.
References
Publications (0)
Data not yet available